Measles, Mumps, and Rubella (MMR) Immunity in College Students

NCT00962819 | Completed

• 1 other identifier: IRB00007373
• Study Type: observational
• Target: 74
• Locations: 1 country
• Sites: 1

Brief Summary

This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.

Conditions

Measles; Mumps; Rubella

Keywords

Mumps; Immunity; Vaccine; Mumps antibodies; Mumps immunity

Outcome Measures

Primary Outcomes (1)

• Levels of mumps antibody and levels of memory B and T cell responses

  Cross sectional measurement of antibodies to mumps. measles or rubella

  Day 1 for all participants except for those who receive MMR vaccine, there will be additional outcome measures on Day 0, 7, 14 and 28 post-vaccination.

Secondary Outcomes (1)

• Determine proportion of college-aged students who are seronegative for mumps

  outcome measurement on Day 1

Study Arms (1)

cross-sectional

College-aged students who were immunized with MMR.

Biological: MMR vaccine

Interventions

MMR vaccine BIOLOGICAL

People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)

Also known as: No other names

cross-sectional

Eligibility Criteria

• Age: 18 Years - 24 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Subjects for this study will be 18-22 year olds recruited from Emory University's student population who have received two age-appropriate doses of the MMR-II vaccine.

You may qualify if:

• Ability and willing to provide an informed consent
• Documented receipt of MMR-II vaccination in childhood
• Not pregnant

You may not qualify if:

• No history of HIV infection.
• Immunocompromised health status due to HIV infection, cancer, diabetes, liver, lung or kidney diseases, autoimmune diseases, history of splenectomy.
• Use of immunosuppressive medications within last 2 to 3 months (oral or parenteral corticosteroids or cytotoxic medications)
• Medical conditions that require the use of immunosuppressive medications
• Received blood or blood products within the last 30 days
• Any vaccines received in the last 30 days

Sponsors & Collaborators

• Sri Edupuganti, MD MPH: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

The Hope Clinic of the Emory Vaccine Center

Decatur, Georgia, 30030, United States

Location

Related Publications (2)

• Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, Hunt K, Finley CG, Leschinsky DP, O'Keefe AL, Clayton J, Kightlinger LK, Dietle EG, Berg J, Kenyon CL, Goldstein ST, Stokley SK, Redd SB, Rota PA, Rota J, Bi D, Roush SW, Bridges CB, Santibanez TA, Parashar U, Bellini WJ, Seward JF. Recent resurgence of mumps in the United States. N Engl J Med. 2008 Apr 10;358(15):1580-9. doi: 10.1056/NEJMoa0706589.

  PMID: 18403766 BACKGROUND

• Rasheed MAU, Hickman CJ, McGrew M, Sowers SB, Mercader S, Hopkins A, Grimes V, Yu T, Wrammert J, Mulligan MJ, Bellini WJ, Rota PA, Orenstein WA, Ahmed R, Edupuganti S. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19071-19076. doi: 10.1073/pnas.1905570116. Epub 2019 Sep 3.

  PMID: 31481612 RESULT

Related Links

• website for vaccine research clinic

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood

MeSH Terms

Conditions

Measles; Mumps; Rubella

Interventions

Measles-Mumps-Rubella Vaccine

Condition Hierarchy (Ancestors)

Morbillivirus Infections; Paramyxoviridae Infections; Mononegavirales Infections; RNA Virus Infections; Virus Diseases; Infections; Rubulavirus Infections; Parotitis; Parotid Diseases; Salivary Gland Diseases; Mouth Diseases; Stomatognathic Diseases; Rubivirus Infections; Togaviridae Infections

Intervention Hierarchy (Ancestors)

Vaccines, Combined; Vaccines; Biological Products; Complex Mixtures; Measles Vaccine; Viral Vaccines; Mumps Vaccine; Rubella Vaccine

Study Officials

• Srilatha Edupuganti, MD

  Emory University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Prfessor

Study Record Dates

• First Submitted: May 19, 2008
• First Posted: August 20, 2009
• Study Start: March 1, 2010
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: October 8, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)